|
Bruce Eaton is a Professor of Chemistry at North Carolina State University. Dr. Eaton was Vice President of Chemistry at NeXstar Pharmaceuticals, Inc. (1994-1999) where he directed the efforts of over 50 scientists and managed the group responsible for the production of the first successful aptamer IND, NX1838, for age-related macular degeneration. In 1998, he led the business development efforts that resulted in the spinout of the chemistry company Proligo LLC, which led to NeXstar achieving profitability that year. Also during his years at NeXstar Pharmaceuticals, Dr. Eaton was a Professor of Chemistry at Washington State University, a position he held there since 1989. Dr. Eaton is named as inventor on more than 25 issued patents and has authored more than 50 peer-reviewed publications and scientific meeting presentations. He received his B.S. and M.S. degrees from the University of Oregon in 1980 and 1981 respectively, and his Ph.D. from the University of California, Berkeley in 1986. | 